REG - Genedrive PLC - Completion of Placing

GenedriveAnnouncement

24/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250924:nRSX5308Aa&default-theme=true

RNS Number : 5308A  Genedrive PLC  24 September 2025

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN
OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO
DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR
REGULATION.

 

FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY
OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO
ANY PERSON SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN GENEDRIVE PLC IN ANY
JURISDICTION.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF
REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF
16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF
UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

 

UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

24 September 2025

 

genedrive plc

("genedrive", the "Group" or the "Company")

Completion of Placing

 

Manchester, UK - 24 September 2025: genedrive plc (LSE: GDR), the point of
care pharmacogenetic testing company, announces the completion of the Placing
(incorporating the Firm Placing and the Conditional Placing). This follows the
Company announcing the launch of an accelerated bookbuild yesterday at 4.59
p.m. (the "Launch Announcement"). The new Ordinary Shares to be allotted
pursuant to the Placing (the "Placing Shares") are to be issued at the Issue
Price of 0.20 pence per Placing Share. The Placing Shares will entitle Placees
to Warrants, conditional on the passing of the Resolutions at the forthcoming
general meeting of the Company and admission of the Conditional Placing
Shares, as detailed in the Launch Announcement.

 

The Company has successfully placed 1,598,750,000 Placing Shares at the Issue
Price with investors made up as to 400,000,000 Firm Placing Shares and
1,198,750,000 Conditional Placing Shares raising gross proceeds of
approximately £3.2 million.

 

In addition to the Placing, the Company announced a separate retail offer via
BookBuild yesterday at 5.03 p.m. and this is expected to remain open until
4.35 p.m. on 26 September 2025.

 

400,000,000 Firm Placing Shares will be issued and allotted under the
Company's existing share capital authorities. 1,198,750,000 Conditional
Placing Shares and such number of Retail Offer Shares that are subscribed for
and all Warrants will be issued and allotted conditional on shareholder
approval at the General Meeting expected to be convened for mid-October 2025.
The Company expects to post the circular, including the notice of General
Meeting in the coming days.

 

The Fundraising (excluding the Firm Placing) is conditional on, amongst other
matters, the passing of the Resolutions at the General Meeting. It is expected
that the Firm Placing will complete on or around 8.00 a.m. on 26 September
2025, being the expected date of Admission of the Firm Placing Shares. The
Placing is also conditional upon the Placing Agreement between the Company and
Peel Hunt becoming unconditional and not being terminated in accordance with
its terms.

 

The Firm Placing Shares and the Conditional Placing Shares represent 256 per
cent. of the issued ordinary share capital of the Company prior to the
Fundraising. The Issue Price represents a discount of 64 per cent. to the
closing price of 0.56 pence on 22 September 2025 (being the latest practicable
date prior to the announcement of the Placing).  Up to a further 159,875,000
Retail Offer Shares may be issued pursuant to the Retail Offer.  No part of
the Fundraising is being underwritten.

 

Such number of Placing Shares and Retail Offer Shares will, when issued, be
credited as fully paid and will be issued subject to the Company's articles of
association and will rank pari passu in all respects with the existing issued
ordinary shares in the capital of the Company, including the right to receive
all dividends and other distributions declared, made or paid on or in respect
of such shares by reference to a record date falling after their issue.

 

Application will be made to the London Stock Exchange for the Firm Placing
Shares, the Conditional Placing Shares and such number of Retail Offer Shares
as may be subscribed for to be admitted to trading on AIM ("Admission"). It is
expected that Admission of the Firm Placing Shares will occur at 8.00 a.m. on
26 September 2025 (or such later date as the Company, Peel Hunt and Allenby
Capital may agree, being no later than 8.00 a.m. on 10 October 2025).  It is
expected that Admission of the Conditional Placing Shares and such number of
the Retail Offer Shares as are subscribed for will occur at 8.00 a.m. on 16
October 2025 (or such later date as the Company, Peel Hunt and Allenby Capital
may agree, being no later than 8.00 a.m. on 30 October 2025).

 

Possible further investment

 

The Company has received an additional indication of interest from a
prospective investor to invest in the region of £0.1 million in the Company
on the same terms as the Placing. Discussions remain ongoing with this
prospective investor to finalise binding commitments and will make a further
announcement as appropriate.

 

General Meeting and Placing Agreement

 

The Circular containing a notice convening the General Meeting will be posted
to Shareholders over the coming days. The General Meeting is expected to be
convened for 15 October 2025. Further details will be set out in the Circular.

 

The Placing Agreement is conditional, amongst other things, upon the
following:

 

·    the Minimum Proceeds being raised;

 

·    the passing, without amendment, of Resolutions 1 and 2 at the General
Meeting;

 

·    none of the warranties contained in the Placing Agreement, in the
opinion of Peel Hunt and Allenby Capital (acting in good faith), being untrue
or inaccurate or misleading at the date of the Placing Agreement or becoming
untrue or inaccurate or misleading at any time between such date and Second
Admission by reference to the facts and circumstances from time-to-time
subsisting;

 

·    the Company having complied with all of its obligations under the
Placing Agreement which fall to be performed or satisfied on or prior to First
Admission or Second Admission; and

 

·    Second Admission occurring by no later than 8.00 a.m. on 16 October
2025 (or such later time and/or date as may be agreed between the Company,
Peel Hunt and Allenby Capital, being no later than 8.00 a.m. on 30 October
2025).

 

If the conditions set out above are not satisfied or waived (where capable of
waiver), the Conditional Placing and the Retail Offer will lapse, and the
Conditional Placing Shares, Warrants and the Retail Offer Shares will not be
allotted and issued and no monies will be received by the Company in respect
of those elements of the Fundraising.

 

Related Party Transactions

 

Gino Miele, Russ Shaw, Ian Gilham and Tom Lindsay ("Participating Directors"),
Directors of the Company, have conditionally agreed to subscribe for such
number of new Ordinary Shares as set out below at the Issue Price, additional
details of which are set out at the end of this announcement. The
Participating Directors are subscribing for Retail Offer Shares at the Issue
Price save for Tom Lindsay who is subscribing for Conditional Placing Shares
at the Issue Price.

 

 Director     Position                                              Number of new Ordinary Shares being subscribed for  Total Ordinary Shares held on Second Admission
 Gino Miele   Chief Executive Officer and Chief Scientific Officer  17,500,000                                          19,702,187
 Russ Shaw    Chief Financial Officer                               16,250,000                                          18,950,000
 Ian Gilham   Non-Executive Chairman                                5,000,000                                           7,505,961
 Tom Lindsay  Non-Executive Director                                3,750,000                                           4,901,605

 

As the Participating Directors are all related parties of the Company pursuant
to the AIM Rules, their participation in the Retail Offer or the Conditional
Placing is a related party transaction for the purposes of AIM Rule 13. With
the exception of the Participating Directors, Chris Yates (the other Director
of the Company independent from the Fundraising) considers, having consulted
with the Company's nominated adviser, Peel Hunt, that the participation in the
Fundraising by the Participating Directors is fair and reasonable insofar as
Shareholders are concerned.

 

Total Voting Rights

 

Following First Admission, the Company's enlarged issued ordinary share
capital will be 1,024,895,408 Ordinary Shares. This figure may be used by
Shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change in
their interest in, the share capital of the Company under the FCA's Disclosure
Guidance and Transparency Rules.

 

Subject to, inter alia, the passing of the Resolutions, a further
announcement will be made in due course in relation to the total number of
voting rights of the Company from Second Admission.

 

Capitalised terms in this announcement shall, unless the context demands
otherwise, bear the meanings given to such terms in the Launch Announcement.

 

This Announcement is made in accordance with the Company's obligations under
Article 17 of UK MAR and the person responsible for arranging release of this
announcement on behalf of the Company is Russ Shaw, CFO.

 

Enquiries:

 

 genedrive plc                                                                 +44 (0) 161 989 0245
 Dr Gino Miele (CEO)

 Russ Shaw (CFO)

 Peel Hunt LLP - Nominated Adviser, Joint Broker and Joint Bookrunner                                                   +44 (0) 20 7148 8900
 James Steel / Benjamin Harris (Investment Banking)
 Sohail Akbar / Nicholas Wilks (ECM)

 Allenby Capital Limited - Joint Bookrunner and Joint Broker                   +44 (0)20 3394 2973

 Nick Athanas / Vivek Bhardwaj (Corporate Finance)                             info@allenbycapital.com

 Amrit Nahal / Kelly Gardiner (Sales & Corporate Broking)

 Walbrook PR - Financial PR & IR Adviser      +44 (0) 20 7933 8780
 Paul McManus / Anna Dunphy                                                    or genedrive@walbrookpr.com

 

 
 

About genedrive plc (http://www.genedriveplc.com (http://www.genedriveplc.com)
)

 

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile and simple to use point of need
pharmacogenetic platform for the diagnosis of genetic variants. This helps
clinicians to quickly access key genetic information that will aid them make
the right choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care healthcare
paradigms. Based in the UK, the Company is at the forefront of Point of Care
pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on
how your individual genetics impact a medicines ability to work for you.
Therefore, by using pharmacogenetics, medicine choices can be personalised,
made safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit,
both developed and validated in collaboration with NHS partners and deployed
on its point of care thermocycler platform. Both tests are single-use
disposable cartridges which are ambient temperature stable, circumventing the
requirement for cold chain logistics. The Directors believe the Genedrive®
MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on
antibiotic use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially otherwise
encountered and with no negative impact on the patient care pathway. Its
CYP2C19 ID Kit which has no comparably positioned competitor currently allows
clinicians to make a decision on the use of Clopidogrel in stroke patients in
70 minutes, ensuring that patients who are unlikely to benefit from or suffer
adverse effects from Clopidogrel receive an alternative antiplatelet
therapeutic in a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care Clinical
Excellence ("NICE") and have been recommended for use in the UK NHS. The
Company has a clear commercial strategy focused on accelerating growth through
maximising in-market sales, geographic and portfolio expansion and strategic
M&A, and operates out of its facilities in Manchester.

 

IMPORTANT NOTICES AND DISCLAIMER

 

This announcement including its appendices (together, this "Announcement") and
the information contained in it is not for publication, release, transmission
distribution or forwarding, in whole or in part, directly or indirectly, in or
into the United States of America, Australia, Canada, Japan or the Republic of
South Africa or any other jurisdiction in which publication, release or
distribution would be unlawful. This Announcement is for information purposes
only and does not constitute an offer to sell or issue, or the solicitation of
an offer to buy, acquire or subscribe for shares in the capital of the Company
in the United States of America, Australia, Canada, Japan or the Republic of
South Africa or any other state or jurisdiction where to do so would be
unlawful. Any failure to comply with these restrictions may constitute a
violation of the securities laws of such jurisdictions. This Announcement has
not been approved by London Stock Exchange or by any other securities
exchange.

 

The new Ordinary Shares and attached Warrants and any Warrant Shares, have not
been, and will not be, registered under the U.S. Securities Act of 1933, as
amended (the "Securities Act") or with any securities regulatory authority of
any state or other jurisdiction of the United States of America and may not be
offered, sold, pledged, taken up, exercised, resold, renounced, transferred or
delivered, directly or indirectly, in or into the United States of America
absent registration under the Securities Act, except pursuant to an exemption
from the registration requirements of the Securities Act and in compliance
with any applicable securities laws of any state or other jurisdiction of the
United States of America. The Placing Shares and attached Warrants and any
Warrant Shares are being offered and sold by the Company outside of the United
States of America in offshore transactions as defined in, and pursuant to,
Regulation S under the Securities Act.

 

This announcement is not being distributed by, nor has it been approved for
the purposes of section 21 of the Financial Services and Markets Act 2000, as
amended ("FSMA"), by a person authorised under FSMA.  This announcement is
being directed to persons in the United Kingdom only in circumstances in which
section 21(1) of FSMA does not apply.

 

Members of the Public are not eligible to take part in the Placing. This
announcement is for information purposes only and is directed only at persons
who are: (1) in Member States of the European Economic Area, qualified
investors as defined in article 2(e) of the Prospectus Regulation (EU)
2017/1129 (the "EU Prospectus Regulation"); (2) in the United Kingdom,
qualified investors as defined in article 2(e) of Prospectus Regulation (EU)
2017/1129 as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018, as amended (the "UK Prospectus Regulation"), who (A)
fall within article 19(5) ("investment professionals") of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended
(the "Order"), or (B) fall within article 49(2)(a) to (d) ("high net worth
companies, unincorporated associations, etc.") of the Order; or (3) are
persons to whom it may otherwise be lawfully communicated; (all such persons
together being referred to as "relevant persons"). This announcement and the
terms and conditions set out herein must not be acted on or relied on by
persons who are not relevant persons. Persons distributing this announcement
must satisfy themselves that it is lawful to do so. Any investment or
investment activity to which this announcement and the terms and conditions
set out herein relates is available only to relevant persons and will be
engaged in only with relevant persons.

 

The new Ordinary Shares (including any Warrant Shares) have not been approved,
disapproved or recommended by the U.S. Securities and Exchange Commission, any
state securities commission in the United States of America or any other U.S.
regulatory authority, nor have any of the foregoing authorities passed upon or
endorsed the merits of the offering of new Ordinary Shares (including any
Warrant Shares). Subject to certain exceptions, the securities referred to
herein may not be offered or sold in the United States of America, Australia,
Canada, Japan or the Republic of South Africa or to, or for the account or
benefit of, any national, resident or citizen of the United States of America,
Australia, Canada, Japan or the Republic of South Africa.

 

No public offering of securities is being made in the United Kingdom, the
United States of America or any other jurisdiction. Offers of the new Ordinary
Shares will either be made pursuant to an exemption under the EU Prospectus
Regulation and the UK Prospectus Regulation (as such terms are defined above)
from the requirement to produce a prospectus or otherwise in circumstances not
resulting in an offer of transferable securities to the public under section
102B of FSMA.

 

This Announcement has been issued by, and is the sole responsibility of, the
Company. No representation or warranty, express or implied, is or will be made
as to, or in relation to, and no responsibility or liability is or will be
accepted by the directors or the Company, or by any of its or their respective
partners, employees, advisers, affiliates or agents as to or in relation to,
the accuracy or completeness of this Announcement or any other written or oral
information made available to or publicly available to any interested party or
its advisers, and any liability therefore is expressly disclaimed.   None of
the information in the Announcement has been independently verified or
approved by Peel Hunt, Allenby Capital or any of their respective partners,
directors, officers, employees, advisers, consultants, affiliates or agents.

 

This Announcement contains inside information for the purposes of Article 7 of
UK MAR, encompassing information relating to the Placing described above, and
is disclosed in accordance with the Company's obligations under Article 17 of
UK MAR. In addition, market soundings (as defined in UK MAR) were taken in
respect of the Placing with the result that certain persons became aware of
inside information, as permitted by UK MAR.  This inside information is set
out in this Announcement. Therefore, upon publication of this announcement,
those persons that received such inside information in a market sounding are
no longer in possession of such inside information relating to the Company and
its securities.

 

Peel Hunt, which is authorised and regulated in the United Kingdom by the FCA
is acting as nominated adviser, joint bookrunner and joint broker to the
Company and no one else in connection with the Placing and is not acting for
and will not be responsible to any person other than the Company for providing
the protections afforded to its clients or for providing advice in relation to
the Placing. Peel Hunt's responsibilities as the Company's nominated adviser
under the AIM Rules for Nominated Advisers are owed solely to London Stock
Exchange and are not owed to the Company or to any Director or to any other
person in respect of his decision to acquire shares in the Company in reliance
on any part of this Announcement.

 

Allenby Capital, which is authorised and regulated in the United Kingdom by
the FCA is acting as joint bookrunner and joint broker to the Company and no
one else in connection with the Placing and is not acting for and will not be
responsible to any person other than the Company for providing the protections
afforded to its clients or for providing advice in relation to the Placing.

 

Except as required under applicable law, neither Peel Hunt, Allenby Capital
nor any of their respective directors, officers, partners, members, employees,
advisers, affiliates or agents assume or accept any responsibility whatsoever
for the contents of the information contained in this Announcement or for any
other statement made or purported to be made by or on behalf of Peel Hunt,
Allenby Capital or any of their affiliates in connection with the Company, the
new Ordinary Shares (including any Warrant Shares) or the Placing.  Peel
Hunt, Allenby Capital and each of their respective directors, officers,
partners, members, employees, advisers, affiliates and agents accordingly
disclaim all and any responsibility and liability whatsoever, whether arising
in tort, contract or otherwise (save as referred to above) in respect of any
statements or other information contained in this Announcement and no
representation or warranty, express or implied, is made by Peel Hunt, Allenby
Capital or any of their respective directors, officers, partners, employees,
advisers, affiliates or agents as to the accuracy, completeness or sufficiency
of the information contained in this Announcement.

 

The distribution of this Announcement and/or the Placing in certain
jurisdictions may be restricted by law. No action has been taken by the
Company, Peel Hunt, Allenby Capital or any of their respective affiliates that
would, or which is intended to, permit an offering of the new Ordinary Shares
(including any Warrant Shares) in any jurisdiction or result in the possession
or distribution of this Announcement or any other offering or publicity
material relating to new Ordinary Shares (including any Warrant Shares) in any
jurisdiction where action for that purpose is required.

 

This Announcement does not constitute a recommendation concerning any
investor's option with respect to the Placing. Each investor or prospective
investor should conduct his, her or its own investigation, analysis and
evaluation of the business and data described in this Announcement and
publicly available information. The price and value of securities can go down
as well as up. Past performance is not a guide to future performance.   The
contents of this Announcement are not to be construed as legal, business,
financial or tax advice. Each investor or prospective investor should consult
with his or her or its own legal adviser, business adviser, financial adviser
or tax adviser for legal, financial, business or tax advice.

 

Persons (including without limitation, nominees and trustees) who have a
contractual right or other legal obligations to forward a copy of this
Announcement should seek appropriate advice before taking any action.

 

Neither the content of the Company's website nor any website accessible by
hyperlinks on the Company's website is incorporated in, or forms part of, this
Announcement.

 

Product Governance Requirements

 

Solely for the purposes of the product governance requirements of Chapter 3 of
the FCA Handbook Product Intervention and Product Governance Sourcebook (the
"UK Product Governance Requirements") and/or any equivalent requirements
elsewhere to the extent determined to be applicable, and disclaiming all and
any liability, whether arising in tort, contract or otherwise, which any
"manufacturer" (for the purposes of the UK Product Governance Requirements
and/or any equivalent requirements elsewhere to the extent determined to be
applicable, may otherwise have with respect thereto, the Placing Shares and
any Warrant Shares have been subject to a product approval process, which has
determined that the Placing Shares and any Warrant Shares are: (i) compatible
with an end target market of retail investors and investors who meet the
criteria of professional clients and eligible counterparties, each defined in
Chapter 3 of the FCA Handbook Conduct of Business Sourcebook; and (ii)
eligible for distribution through all permitted distribution channels (the
"Target Market Assessment"). Notwithstanding the Target Market Assessment,
distributors should note that: the price of the Placing Shares and any Warrant
Shares may decline and investors could lose all or part of their investment;
the Placing Shares and any Warrant Shares offer no guaranteed income and no
capital protection; and an investment in the Placing Shares and any Warrant
Shares is compatible only with investors who do not need a guaranteed income
or capital protection, who (either alone or in conjunction with an appropriate
financial or other adviser) are capable of evaluating the merits and risks of
such an investment and who have sufficient resources to be able to bear any
losses that may result therefrom. The Target Market Assessment is without
prejudice to the requirements of any contractual, legal or regulatory selling
restrictions in relation to the Placing. Furthermore, it is noted that,
notwithstanding the Target Market Assessment, Peel Hunt and Allenby Capital
will only procure investors who meet the criteria of professional clients and
eligible counterparties.

 

For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of
Chapters 9A or 10A respectively of the FCA Handbook Conduct of Business
Sourcebook; or (b) a recommendation to any investor or group of investors to
invest in, or purchase, or take any other action whatsoever with respect to
the Placing Shares and any Warrant Shares.

 

Each distributor is responsible for undertaking its own target market
assessment in respect of the Placing Shares and any Warrant Shares and
determining appropriate distribution channels.

 

Forward Looking Statements

 

This Announcement contains "forward-looking statements" which include all
statements (other than statements of historical facts) including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations, and any statements
preceded by, followed by or that include the words "targets", "believes",
"expects", "aims", "intends", "will", "may", "anticipates", "would", "could"
or "similar" expressions or negatives thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors
beyond the Company's control that could cause the actual results, performance
or achievements of the Group to be materially different from future results,
performance or achievements expressed or implied by such forward-looking
statements. Such forward-looking statements are based on numerous assumptions
regarding the Group's present and future business strategies and the
environment in which the Group will operate in the future. These
forward-looking statements speak only as at the date of this Announcement. The
Company expressly disclaims any obligation or undertaking to disseminate any
updates or revisions to any forward-looking statements contained herein to
reflect any change in the Company's expectations with regard thereto or any
change in events, conditions or circumstances on which any such statements are
based unless required to do so by applicable law or the AIM Rules for
Companies.

 

No statement in this Announcement is intended to be a profit forecast and no
statement in this Announcement should be interpreted to mean that earnings per
share of the Company for the current or future years would necessarily match
or exceed the historical published earnings per share of the Company.

 

This Announcement does not constitute a recommendation concerning any
investor's investment decision with respect to the Placing. In addition, this
Announcement does not identify or suggest, or purport to identify or suggest,
the risks (direct or indirect) that may be associated with an investment in
the Placing Shares and any Warrant Shares.

 

Any investment decisions to buy Placing Shares in the Placing must be made
solely on the basis of publicly available information which has not been
independently verified by Peel Hunt or Allenby Capital.

 

The new Ordinary Shares will not be admitted to trading on any stock exchange
other than the AIM market of the London Stock Exchange.

 

The price and value of securities can go down as well as up. Past performance
is not a guide to future performance.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Gino Miele
 2    Reason for the notification
 a)   Position/status                                              Chief Executive Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         genedrive plc
 b)   LEI                                                          213800ZYODIRZ87Y4K14
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of 0.015p each

      Identification code                                          ISIN: GB00B1VKB244
 b)   Nature of the transaction                                    Purchase of ordinary shares
 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     0.20 pence        17,500,000

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price
 e)   Date of the transaction                                      24 September 2025
 f)   Place of the transaction                                     Outside of a trading venue

 

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Russ Shaw
 2    Reason for the notification
 a)   Position/status                                              Chief Financial Officer
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         genedrive plc
 b)   LEI                                                          213800ZYODIRZ87Y4K14
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of 0.015p each

      Identification code                                          ISIN: GB00B1VKB244
 b)   Nature of the transaction                                    Purchase of ordinary shares
 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     0.20 pence        16,250,000

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price
 e)   Date of the transaction                                      24 September 2025
 f)   Place of the transaction                                     Outside of a trading venue

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Ian Gilham
 2    Reason for the notification
 a)   Position/status                                              Chairman
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         genedrive plc
 b)   LEI                                                          213800ZYODIRZ87Y4K14
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of 0.015p each

      Identification code                                          ISIN: GB00B1VKB244
 b)   Nature of the transaction                                    Purchase of ordinary shares
 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     0.20 pence        5,000,000

 d)   Aggregated information                                       N/A

      - Aggregated volume
      - Price
 e)   Date of the transaction                                      24 September 2025
 f)   Place of the transaction                                     Outside of a trading venue

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Tom Lindsay
 2    Reason for the notification
 a)   Position/status                                              Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         genedrive plc
 b)   LEI                                                          213800ZYODIRZ87Y4K14
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of 0.015p each

      Identification code                                          ISIN: GB00B1VKB244
 b)   Nature of the transaction                                    Purchase of ordinary shares
 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     0.20 pence        3,750,000

 d)   Aggregated information                                        N/A

      - Aggregated volume
      - Price
 e)   Date of the transaction                                      24 September 2025
 f)   Place of the transaction                                     Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIFFFVLAIIVFIE